


Formula #: 1805
Rev #:1
Date: May 8, 2024



102-2440 Canoe Ave
Coquitlam BC V3K 6C2
Canada

Benzocaine 20%, Lidocaine 6%, and Tetracaine 4% Transderma MultiMax Cream Base

Ingredients	For 100 g
Benzocaine	20 g
Lidocaine	6 g
Tetracaine	4 g
Polysorbate 80	4 mL
Butylated Hydroxytoluene	0.1 gram
Transderma MultiMax Base	qs 100 g

Application:

Used as a topical numbing agent.¹⁻³

Note:

This preparation should be prepared in a vertical airflow hood in a biological safety cabinet or barrier isolation technology. Disposable equipment is appropriate for this preparation.

Compounding Procedure:⁴


1. Calculate the required quantity of each ingredient for the total amount to be prepared
2. Accurately weigh and/or measure each ingredient
3. Geometrically mix the benzocaine, lidocaine and tetracaine powder together until well blended
4. Add the polysorbate 80 and butylated hydroxytoluene (BHT) to the powder mixture combining well
5. Geometrically incorporate the powder mixture into the Transderma MultiMax cream base. QS to final dispensed quantity and mix very well.
6. Shear force mixing (electronic mortar & pestle) and/or milling may be necessary to fully distribute the API's throughout the base cream and to facilitate the creation of a pharmaceutically elegant final preparation.
7. Package and label

Packaging and Labelling:

Use under the direct supervision and direction of a qualified healthcare practitioner only. Apply exact dose topically as directed, keep away from eyes and mucous membranes, apply very sparingly to affected area, keep out of reach of children, protect from light and moisture, do not cover treated area with occlusive dressing(s). Store at controlled room temperature away from excessive heat

Disclaimer: Xenex Laboratories Inc. has provided the formula and instructions above as a model for educational purposes only on the basis of recognized compendia and texts or references. Xenex Laboratories Inc. takes no responsibility for the validity or accuracy of this information or for its safety or effectiveness, nor for any use thereof, which is at the sole risk of the licensed pharmacist. Adjustments may be needed to meet specific patient needs and in accordance with a licensed prescriber's prescription. The pharmacist must employ appropriate tests to determine the stability of this suggested formula. Xenex Laboratories Inc., its owners, officers, agents, contractors, affiliates and employees cannot be held liable to any person or entity concerning claims, loss or damage caused by, or alleged to be caused by, directly or indirectly, the use or misuse of the information contained in this suggested formula. In all cases, it is the responsibility of the licensed pharmacist to know the law, to compound any finished product and to dispense these products in accordance with Health Canada and FDA guidelines and appropriate Provincial Drug Schedules and Provincial or Territorial Pharmacy Practice Standards.

Formula #: 1805
Rev #:1
Date: May 8, 2024



102-2440 Canoe Ave
Coquitlam BC V3K 6C2
Canada

Beyond Use Date:

30 days^{4,5}

References:

1. Benzocaine. *UpToDate*. Waltham, MA.: UpToDate; 2023. www.uptodate.com. Accessed May 19, 2023.
2. Lidocaine. *UpToDate*. Waltham, MA.: UpToDate; 2023. www.uptodate.com. Accessed May 19, 2023.
3. Tetracaine. *UpToDate*. Waltham, MA.: UpToDate; 2023. www.uptodate.com. Accessed May 19, 2023.
4. Loyd AV. Benzocaine 20%, Lidocaine 6%, and Tetracaine 4% in Lipoderm. *Int J Pharm Compd*. 2016;20:50
5. National Association of Pharmacy Regulatory Authorities, Guidance Document for Pharmacy Compounding of Non-Sterile Preparations. June 2018

Disclaimer: Xenex Laboratories Inc. has provided the formula and instructions above as a model for educational purposes only on the basis of recognized compendia and texts or references. Xenex Laboratories Inc. takes no responsibility for the validity or accuracy of this information or for its safety or effectiveness, nor for any use thereof, which is at the sole risk of the licensed pharmacist. Adjustments may be needed to meet specific patient needs and in accordance with a licensed prescriber's prescription. The pharmacist must employ appropriate tests to determine the stability of this suggested formula. Xenex Laboratories Inc., its owners, officers, agents, contractors, affiliates and employees cannot be held liable to any person or entity concerning claims, loss or damage caused by, or alleged to be caused by, directly or indirectly, the use or misuse of the information contained in this suggested formula. In all cases, it is the responsibility of the licensed pharmacist to know the law, to compound any finished product and to dispense these products in accordance with Health Canada and FDA guidelines and appropriate Provincial Drug Schedules and Provincial or Territorial Pharmacy Practice Standards.